Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096260 · ClinicalTrials.gov registry record · NA
Getting to Yes, Michigan! (G2YMI)
A NA study of COVID-19 Pandemic and COVID-19 Vaccines, sponsored by University of Michigan.
- Active
- Registry status
- NA
- Development phase
- 700
- Enrollment target
- 1
- Study location
NCT05096260: Active NA study of COVID-19 Pandemic and COVID-19 Vaccines, sponsored by University of Michigan.
NCT05096260 is a NA study of COVID-19 Pandemic and COVID-19 Vaccines that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 700 participants, below the 935-participant average among 3 other COVID-19 Pandemic trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096260, a NA study of COVID-19 Pandemic and COVID-19 Vaccines, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
This study entitled Community-Centered Interventions for Improved Vaccine Uptake for COVID-19 (CIVIC): Getting to Yes, Michigan!, is designed to increase vaccine uptake among populations that experience COVID-19 related disparities. The investigators will focus on the four counties within Michigan where a disproportionate burden of COVID-19 is within African Americans and Latinx communities, i.e., Wayne, Genesee, Kent and Washtenaw Counties. Using a community-based participatory research (CBPR) approach, CIVIC will leverage: its long term relationships with the communities involved, an established CBPR Steering Committee developed and the knowledge gained as a Community Engagement Alliance (CEAL) grant recipient, the resources and networks of the University of Michigan CTSA (MICHR), and the expertise of our academic partners to identify and understand factors that contribute to COVID-19 vaccine hesitancy in African Americans and Latinx communities in Michigan. The investigators will develop and test interventions based on community-centered approaches to achieve a primary goal of increased vaccine uptake. The investigators will achieve this goal with the following aims: 1. Increase understanding of the barriers and drivers of vaccine uptake and hesitancy; 2. Increase vaccine uptake and decrease vaccine hesitancy through the implementation and evaluation of a multi-component intervention; and maintain, enhance, and evaluate the effectiveness of the CIVIC partnership to equitably engage all partners.
Primary Outcome
The primary outcome is the binary variable of participant-reported vaccine uptake.
Conditions Studied
Interventions
- BEHAVIORAL Motivational Interviewing based SMS/MMS and web content
Study Locations (1)
Michigan
- Michigan Medicine - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2026-03-11 |
| Phase | NA |
What the registry record for NCT05096260 still lists
NCT05096260 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 3 other COVID-19 Pandemic trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with COVID-19 Pandemic appearing as the primary indexed condition, and to 1 intervention - of which Motivational Interviewing based SMS/MMS and web content is the first listed.
NCT05096260 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05096260 about?
NCT05096260 is a clinical study titled "Getting to Yes, Michigan! (G2YMI)". This study entitled Community-Centered Interventions for Improved Vaccine Uptake for COVID-19 (CIVIC): Getting to Yes, Michigan!, is designed to increase vaccine uptake among populations that experience COVID-19 related disparities. The investigators will focus on the four counties within Michigan w...
What is the current status of trial NCT05096260?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2022-07-05. Estimated completion is 2026-03-11.
What conditions does trial NCT05096260 study?
This clinical trial studies the following conditions: COVID-19 Pandemic, COVID-19 Vaccines.
What interventions are being tested in trial NCT05096260?
The interventions under investigation include: Motivational Interviewing based SMS/MMS and web content (BEHAVIORAL).
Who is sponsoring clinical trial NCT05096260?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096260 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Pandemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI